Preclinical Oncology: 2020 Spotlight Roundup

2020年已经没有别的一年！在这个前所未有的时期，我们努力使新的模型和技术带入船上的新型和技术，以帮助实现临床前肿瘤和免疫肿瘤药物的相关方法。yaboapp体育官网

An area of continuing growth in the industry has been humanized mouse models. At Covance, we have established a platform using human PBMCs and demonstrated proof of concept in the A549 human non-small cell lung carcinoma and the Mia-PaCa-2 human pancreatic models for both baseline growth and response to pembrolizumab:

• 造型免疫肿瘤学in a humanized mouse://www.wfliji.com/industry-solutions/oncology/preclinical/tumor-spotlights/modeling-immuno-oncology-in-a-humanized-mouse.html
• 免疫脑肿瘤型人PBMC的临床yaboapp体育官网前使用更新：//www.wfliji.com/industry-solutions/oncology/preclinical/tumor-spotlights/update-on-the-preclinical-use-of-hPBMC-for-immuno-oncology-modeling.html

Work on this platform continues as we investigate immune cell responses following treatment with pembrolizumab by flow cytometry.

Another area of exponential growth in our industry has been in the adoptive cell therapy space. To support this sector, our extensive list of human xenograft cell lines (//www.wfliji.com/industry-solutions/oncology/preclinical/complete-cell-line-list/human-cancer-cell-lines-and-growth-curves.html) provides customers with an array of options for both hematologic malignancies and solid tumors. Having the models, however, is only the first step. We havein vivogrowth data on more than 30 of these models in the relevant NSG^TM值mouse strain and we have approximately 100 cell lines that are luciferase enabled. In order to track and monitorin vivo肿瘤负担和对治疗的反应，我们在生物发光成像（BLI）中具有行业领先能力。在成为提供BLI的第一个CRO时，我们拥有最长的经验，在2020年聚光灯下突出显示了这一领域中最相关的模型和无与伦比的专业知识：

• Bioluminescence imaging: In vivo monitoring of tumor development, disease dissemination and treatment efficacy://www.wfliji.com/行业 - 苏 - 持久/普雷克莱普in/tumor-spyaboapp体育官网otlights/bioluminescence-imaging-spotlight.html.

如果您需要支持使用BLI成像运行一项研究reach outtoday!

While having the appropriate model is critical, it’s equally important to have the capabilities required for phenotypic and mechanistic evaluation of therapeutic responses. These phenotypic and mechanistic biomarkers help define actions and outcomes of novel therapies being investigated. This year we expanded our menu of off-the-shelf flow cytometry packages and panels to include more in-depth capabilities around phenotypic analysis of both lymphoid and myeloid populations along with functional analysis of tumor infiltrating leukocytes and CAR T cell persistencein vivo。

迄今为止，我们具有大约20个即可移位的流式细胞术面板和/或包装，其跨越人和小鼠细胞类型，并有助于巩固我们最佳的临床前流式细胞术服务。yaboapp体育官网

Determining preclinical CAR T-cell persistence by flow cytometry://www.wfliji.com/industry-solutions/oncology/preclinical/tumor-spotlights/determining-preclinical-car-t-cell-persistence-by-flow-cytometry.html

用细胞因子/细胞毒性™小组流式细胞仪肿瘤渗透淋巴细胞的功能分析：//www.wfliji.com/industry-solutions/oncology/preclinical/tumor-spotlights/functional-analysis-of-tumor-infiltrating-lymphocytes-by-flow-cytometry.html

通过ELISPOT和Fluorophot测量肿瘤抗原特异性免疫：//www.wfliji.com/industry-solutions/oncology/yaboapp体育官网preclinal/tumor-spotlights/measing-tumor-anitgen-specific-immunity.html.

在另一个不断增长的地区in vitro能力，2020看到了我们的推出in vitrotumor platform that utilizes zPREDICTA®’s organ-specific three-dimensional (3D) culture models. These assays support long-term culture of tumor cells within relevant physiologic extracellular matrix components that have been shown to be critical in maintaining the tumor microenvironment as well as maintaining specific tumor phenotypes. Information around the establishment of the reconstructed bone marrow (r-Bone) 3D platform to support hematologic malignancies or other cancers that home to the bone was highlighted during 2020:

A New Covance Offering: zPREDICTA®’s Reconstructed Bone (r-Bone), plate-based, 3-dimensional (3D) culture assay that mimics the tumor microenvironment found in myeloma, acute myelogenous leukemia and solid tumor metastasis://www.wfliji.com/industry-solutions/oncology/preclinical/tumor-spotlights/reconstructed-bone-3d-model.html

Finally, it wouldn’t be a complete year without bringing some new models onboard or highlighting some of our tried and true models. To this end we shared data and insights on our continued efforts to develop relevant syngeneic orthotopic models:

Pan02-Luc: An orthotopic model of pancreatic cancer://www.wfliji.com/industry-solutions/oncology/yaboapp体育官网preclinal/tumor-spotlights/pan02-luc-an-torthotopic-model-of-pancreatic-cancer.html.

CT26-LUC：结肠癌的原位小鼠模型：免疫肿瘤学研究的影响：//www.wfliji.com/行业 - 侦探/ oncology/tumor-spotyaboapp体育官网lights/ct26-luc-an-torthotopic-murine-model-of-colon-cancer-implications-for-immuno-cology-studies。HTML.

Syngeneic原位模型是美国的积极发展领域，所以在2021年保持调整，以了解更多关于这些方法或者今天伸出援手，从我们的一个科学家学习更多。除了同工模型，我们还将努力重新建立NSG中的人BT474乳房模型^TM值鼠标菌株。这种模式难以与之合作，但在过去几年中已经看到了更新的兴趣。了解2020年期间我们在模型聚光灯中如何在模型中接近此问题：

BT-474 Human ductal breast carcinoma: New life for an old model://www.wfliji.com/industry-solutions/oncology/preclinical/tumor-spotlights/bt-474-human-ductal-breast-carcinoma.html

As we embark on 2021, we aim to continue our pursuit of bringing on additional models and assays to help you advance your novel oncology and immuno-oncology assets. There are many ongoing initiatives that will come to fruition during 2021 and, as always, we look to the future for approaches to continue expanding our preclinical oncology and immuno-oncology solutions for your drug discovery and development needs.

所有动物在有关聚光灯是应用程序工作roved by the site Institutional Animal Care and Use Committee and was performed in conformance with the Guide for the Care and Use of Laboratory Animals within an AAALAC-accredited program with humane euthanasia criteria predetermined on all studies.

We’d love to hear from you. Tell us what you’re looking for and how we can help support you in your drug development process!

作者：

Maryland Franklin, PhD | Executive Director, Scientific Development

DATE:

January 2021